Trkola A - Search Results

1

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent.

Reh L, Magnus C, Schanz M, Weber J, Uhr T, Rusert P, Trkola A. Reh L, et al. Among authors: trkola a. PLoS Pathog. 2015 Jul 9;11(7):e1004966. doi: 10.1371/journal.ppat.1004966. eCollection 2015 Jul. PLoS Pathog. 2015. PMID: 26158270 Free PMC article.

2

Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.

Rusert P, Fischer M, Joos B, Leemann C, Kuster H, Flepp M, Bonhoeffer S, Günthard HF, Trkola A. Rusert P, et al. Among authors: trkola a. Virology. 2004 Aug 15;326(1):113-29. doi: 10.1016/j.virol.2004.05.022. Virology. 2004. PMID: 15262500 Free article.

3

Complement dependent trapping of infectious HIV in human lymphoid tissues.

Bánki Z, Kacani L, Rusert P, Pruenster M, Wilflingseder D, Falkensammer B, Stellbrink HJ, van Lunzen J, Trkola A, Dierich MP, Stoiber H. Bánki Z, et al. Among authors: trkola a. AIDS. 2005 Mar 25;19(5):481-6. doi: 10.1097/01.aids.0000162336.20439.8d. AIDS. 2005. PMID: 15764853 Clinical Trial.

4

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Trkola A, et al. Nat Med. 2005 Jun;11(6):615-22. doi: 10.1038/nm1244. Epub 2005 May 8. Nat Med. 2005. PMID: 15880120 Clinical Trial.

5

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A. Rusert P, et al. Among authors: trkola a. J Virol. 2005 Jul;79(13):8454-69. doi: 10.1128/JVI.79.13.8454-8469.2005. J Virol. 2005. PMID: 15956589 Free PMC article.

6

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Joos B, Trkola A, Fischer M, Kuster H, Rusert P, Leemann C, Böni J, Oxenius A, Price DA, Phillips RE, Wong JK, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study. Joos B, et al. Among authors: trkola a. J Virol. 2005 Jul;79(14):9026-37. doi: 10.1128/JVI.79.14.9026-9037.2005. J Virol. 2005. PMID: 15994796 Free PMC article.

7

Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.

Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederöst B, Weber R, von Wyl V, Günthard HF, Trkola A. Huber M, et al. Among authors: trkola a. PLoS Med. 2006 Nov;3(11):e441. doi: 10.1371/journal.pmed.0030441. PLoS Med. 2006. PMID: 17121450 Free PMC article.

8

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.

Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederöst B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A. Manrique A, et al. Among authors: trkola a. J Virol. 2007 Aug;81(16):8793-808. doi: 10.1128/JVI.00598-07. Epub 2007 Jun 13. J Virol. 2007. PMID: 17567707 Free PMC article.

Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals with monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 provided evidence of the in vivo activity of 2G12 but raised concerns about the function of the two membrane-proximal external region (M …

Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals with monoclonal antibodies (MAbs) 2G12, 2F5, and 4 …

9

In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers.

Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, Stiegler G, Katinger H, Joos B, Günthard HF. Trkola A, et al. J Virol. 2008 Feb;82(3):1591-9. doi: 10.1128/JVI.01792-07. Epub 2007 Nov 21. J Virol. 2008. PMID: 18032508 Free PMC article.

10

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics.

Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthésy S, Turville SG, Aravantinou M, Fischer M, Robbiani M, Amstutz P, Trkola A. Schweizer A, et al. Among authors: trkola a. PLoS Pathog. 2008 Jul 25;4(7):e1000109. doi: 10.1371/journal.ppat.1000109. PLoS Pathog. 2008. PMID: 18654624 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

458 results

Search Page

Filters